Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q3 2016 call → NOWe need to determine if the call describes real business activity that started during or around the period, and that the climb is incomplete, with reported numbers lagging. The transcript is about Supernus Pharmaceuticals Q3 2016. Key points: They have commercial products Trokendi XR and Oxtellar XR. They mention strong growth in prescriptions and net product sales. They also mention pipeline: SPN-810 and SPN-812. For SPN-812, they announced positive top-line results from Phase 2b trial in October (after Q3). That's a clinical trial result, not a commercial start. For SPN-810, enrollment continues. No new product launches. The only thing that might be a start is the migraine indication for Trokendi XR: FDA granted tentative approval during Q3, and they are preparing to launch after full approval. But that launch has not yet occurred; it's still pending full approval. So that's a future launch, not a start in the period. Also, they mention business development activities but no specific deals. The restatement is an accounting issue, not business activity. So there is no real business activity that began during the period. The company's revenue growth is from existing products. No new product launches or capacity. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.